NewLimit CEO: AI Can't Fix Biological Latency in Clinical Trials
jacobkimmel · x · 2026-09-02
NewLimit CEO Jacob Kimmel explains the limitations of AI in expediting clinical trials, citing "irreducible latencies" in biology that differ from bandwidth and latency in computer science.
- Biological Constraints: For example, observing a drug's effect on a patient requires a full month; enrolling 30 patients does not allow checking results in one day.
- AI's Potential Role: While absolute time cannot be shortened, AI may improve success rates. Currently, about 90% of drugs entering clinical trials fail. Doubling the success rate to 20% would be a significant achievement.
More from Companies & People
- Hacktoberfest 2026 Shifts From Open-Source Contributions to Open AI Community Events — jonmarkgo · 2026-09-02
- Broadcom's VMware Private AI Push Signals Enterprise AI Moving From Pilots to Production — DavidLinthicum · 2026-09-02
- UT PGE Faculty Discuss AI Strategy for Teaching and Research — GeostatsGuy · 2026-09-02
- Meta's Return to AI Front Rank: Strategy and Stats — rohanpaul_ai · 2026-09-02
- Berkeley professor joins TransluceAI as senior research fellow — 2plus2make5 · 2026-09-02
- Pentium chip father Vinod Dham discusses AI and longevity — Chris_Armstrong · 2026-09-02